HC Wainwright Reiterates Sell Rating for Sarepta Therapeutics (NASDAQ:SRPT)

Sarepta Therapeutics (NASDAQ:SRPTGet Free Report)‘s stock had its “sell” rating reaffirmed by analysts at HC Wainwright in a report released on Wednesday, June 25th,Benzinga reports.

A number of other research analysts have also recently commented on the company. Oppenheimer reduced their price objective on Sarepta Therapeutics from $123.00 to $45.00 and set an “outperform” rating on the stock in a research note on Friday, June 20th. Barclays reduced their price target on Sarepta Therapeutics from $89.00 to $29.00 and set an “overweight” rating on the stock in a research report on Tuesday, June 17th. Deutsche Bank Aktiengesellschaft dropped their price objective on shares of Sarepta Therapeutics from $50.00 to $25.00 and set a “hold” rating on the stock in a research note on Tuesday, June 17th. Robert W. Baird reduced their target price on shares of Sarepta Therapeutics from $60.00 to $30.00 and set an “outperform” rating on the stock in a research report on Tuesday, June 17th. Finally, JPMorgan Chase & Co. lowered their price target on shares of Sarepta Therapeutics from $169.00 to $84.00 and set an “overweight” rating for the company in a report on Tuesday, May 20th. One analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and twelve have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $60.88.

Check Out Our Latest Report on Sarepta Therapeutics

Sarepta Therapeutics Trading Up 2.7%

Shares of NASDAQ:SRPT traded up $0.48 during trading on Wednesday, reaching $18.19. 4,622,615 shares of the stock were exchanged, compared to its average volume of 2,180,775. The firm’s 50-day moving average price is $37.88 and its 200 day moving average price is $77.32. Sarepta Therapeutics has a 12-month low of $16.88 and a 12-month high of $155.95. The company has a quick ratio of 2.46, a current ratio of 4.02 and a debt-to-equity ratio of 1.00.

Sarepta Therapeutics (NASDAQ:SRPTGet Free Report) last released its quarterly earnings data on Tuesday, May 6th. The biotechnology company reported ($3.42) earnings per share (EPS) for the quarter, missing the consensus estimate of $2.20 by ($5.62). Sarepta Therapeutics had a negative return on equity of 14.88% and a negative net margin of 11.12%. The business had revenue of $744.86 million during the quarter, compared to analyst estimates of $685.75 million. During the same period in the previous year, the company earned $0.73 EPS. Sarepta Therapeutics’s revenue was up 80.2% on a year-over-year basis. Equities analysts forecast that Sarepta Therapeutics will post 2.67 earnings per share for the current year.

Institutional Trading of Sarepta Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Exchange Traded Concepts LLC acquired a new position in shares of Sarepta Therapeutics during the first quarter valued at approximately $479,000. GAMMA Investing LLC boosted its stake in Sarepta Therapeutics by 4,682.8% during the first quarter. GAMMA Investing LLC now owns 40,845 shares of the biotechnology company’s stock valued at $2,607,000 after buying an additional 39,991 shares in the last quarter. Charles Schwab Investment Management Inc. raised its position in Sarepta Therapeutics by 2.0% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 623,749 shares of the biotechnology company’s stock worth $75,842,000 after acquiring an additional 12,000 shares in the last quarter. Proficio Capital Partners LLC bought a new position in shares of Sarepta Therapeutics during the 4th quarter valued at about $3,829,000. Finally, PNC Financial Services Group Inc. grew its stake in shares of Sarepta Therapeutics by 5.3% in the 4th quarter. PNC Financial Services Group Inc. now owns 2,891 shares of the biotechnology company’s stock worth $352,000 after purchasing an additional 145 shares during the last quarter. 86.68% of the stock is currently owned by institutional investors.

Sarepta Therapeutics Company Profile

(Get Free Report)

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.

Further Reading

Analyst Recommendations for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.